DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Gefapixant is an investigational drug.
There have been 8 clinical trials for Gefapixant. The most recent clinical trial was a Phase 2 trial, which was initiated on March 14th 2018.
The most common disease conditions in clinical trials are Cough, Endometriosis, and Respiratory Tract Infections. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Afferent Pharmaceuticals, Inc., and [disabled in preview].
There are fourteen US patents protecting this investigational drug and one hundred and fifteen international patents.
Recent Clinical Trials for Gefapixant
|A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038)||Merck Sharp & Dohme Corp.||Phase 3|
|A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034)||Merck Sharp & Dohme Corp.||Phase 2|
|Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013)||Merck Sharp & Dohme Corp.||Phase 2|
Top disease conditions for Gefapixant
Top clinical trial sponsors for Gefapixant
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Gefapixant||Start Trial||Methods and compositions for treating diseases and conditions||Afferent Pharmaceuticals, Inc. (San Mateo, CA)||Start Trial|
|Gefapixant||Start Trial||Substituted pyrimidines for treatment of chronic cough, neuronal hypersensitivity underlying chronic cough, neuronal hypersensitivity underlying sub-acute cough and neuronal hypersensitivity underlying acute cough||Afferent Pharmaceuticals, Inc. (San Mateo, CA)||Start Trial|
|Gefapixant||Start Trial||Diaminopyrimidines as P2X.sub.3 and P2X.sub.2/3 antagonists||Roche Palo Alto LLC (Palo Alto, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Gefapixant||European Patent Office||3164132||2034-07-03||Start Trial|
|Gefapixant||World Intellectual Property Organization (WIPO)||2016004358||2034-07-03||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|